DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

424 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2016-05-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary objective:

* To demonstrate the non-inferiority in terms of seroprotection rates (Hib antigen (PRP), Diphtheria, Tetanus, and Pertussis antigens (PT and FHA), and polio types 1, 2 and 3 antigens) of investigational arm (Group A: DTaP-IPV/Hib) versus control arm (Group B: DTaP-IPV and Hib vaccines administered at separate sites), one month after the primary vaccination (all antigens).

Secondary objectives:

* To describe immune responses against all vaccine antigens with no pre-specified hypothesis, and at all time points (pre-dose 1, post-dose 3, pre-dose 4 and post-dose 4) in the two study groups (Group A and Group B).
* To describe the safety after each dose of each vaccine in the two study groups (Group A and Group B).
* To describe immune responses against all vaccine antigens with no pre-specified hypothesis, and at all time points (pre-dose 1, post-dose 3, pre-dose 4 and post-dose 4 (Group C)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children

NCT01125527

Haemophilus Influenzae Type b (Hib) Infection

COMPLETED PHASE3

Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)

NCT01926015

Rotavirus Disease

COMPLETED PHASE4

Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants

NCT00879827

Diphtheria Poliomyelitis Hepatitis B +2 more

COMPLETED PHASE3

Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan

NCT01389687

Poliomyelitis Polio

COMPLETED PHASE3

Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine

NCT00325143

Haemophilus Influenzae Type b Diphtheria Tetanus +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will be enrolled in two steps (Cohort 1 and Cohort 2). Step one will enroll Cohort 1 made of 40 participants randomized in two groups with a 1:1 ratio.

After review of the local and systemic adverse events occurring during the 7 Days following the first dose administered in these subjects, 2nd vaccination of Cohort 1 participants will resume and enrollment of the participants of Cohort number 2 will start. Step two will enroll Cohort 2 made of subjects randomized in two groups with a 1:1 ratio.

A sub-study Group C will be enrolled and will receive the vaccine by intramuscular route.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tetanus Diphtheria Pertussis Poliomyelitis Bacterial Meningitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A (SP0204)

Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously

Group Type EXPERIMENTAL

DTaP-IPV/Hib Combined vaccine

Intervention Type BIOLOGICAL

0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart

Group B (control)

Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously

Group Type ACTIVE_COMPARATOR

DTaP-IPV vaccine and Hib vaccine

Intervention Type BIOLOGICAL

0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart

Group C

Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly

Group Type EXPERIMENTAL

DTaP-IPV/Hib Combined vaccine

Intervention Type BIOLOGICAL

0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DTaP-IPV/Hib Combined vaccine

0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart

Intervention Type BIOLOGICAL

DTaP-IPV vaccine and Hib vaccine

0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart

Intervention Type BIOLOGICAL

DTaP-IPV/Hib Combined vaccine

0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SP0204 DD 687; DF 098 SP0204

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 2 months to 68 months inclusive (recommended 3 to 8 months for Groups A and B; 2 months for Group C) on the day of inclusion
* Informed consent form signed by the parent(s) or other legal representative
* Able to attend all scheduled visits and to comply with all trial procedures.

Exclusion Criteria

* Fever ≥ 37.5°C (axillary temperature) on the day of inclusion
* Any serious disease whether acute or chronic
* Past or current medical history of Guillain-Barre syndrome, acute thrombocytopenic purpura or encephalopathy
* History of diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b infections
* History of a life threatening reaction to a vaccine containing the same substances of the study vaccine
* History of anaphylaxis to any of the study vaccine components
* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis or Haemophilus influenzae type b infections with a trial vaccine or another vaccine
* Congenital or current acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy
* Participation in another clinical trial preceding the trial inclusion
* Planned participation in another clinical trial during the present trial period
* Blood or blood-derived products received in the past or current or planned administration during the trial (including immunoglobulins)
* Any vaccination with live vaccines within the past 27 days preceding the first trial vaccination
* Any vaccination with inactivated vaccines within the past 6 days preceding the first trial vaccination
* Clinical or known serological evidence of systemic illness including Hepatitis B, Hepatitis C and/or HIV infection
* Subject ineligible according to the Investigator's clinical judgment
* Identified as employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family member (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.

Minimum Eligible Age

2 Months

Maximum Eligible Age

68 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes